These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 24372512)

  • 21. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
    Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
    Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.
    Shiseki M; Ishii M; Okada M; Ohwashi M; Wang YH; Osanai S; Yoshinaga K; Mori N; Motoji T; Tanaka J
    Leuk Res; 2019 Sep; 84():106175. PubMed ID: 31299412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
    Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
    Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome.
    Douet-Guilbert N; Laï JL; Basinko A; Gueganic N; Andrieux J; Pollet B; Plantier I; Delattre C; Crépin O; Corm S; Le Bris MJ; Morel F; De Braekeleer M
    Br J Haematol; 2008 Dec; 143(5):716-20. PubMed ID: 19036015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes.
    Kawankar N; Jijina F; Ghosh K; Vundinti BR
    Cancer Epidemiol; 2011 Aug; 35(4):e1-5. PubMed ID: 21193364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
    Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
    Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and molecular cytogenetic features of myeloid diseases characterized by i(20q-): a study of seven cases].
    Li TY; Xue YQ; Wu YF; Pan JL; Liu DD; Gong SL
    Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):732-5. PubMed ID: 15200909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
    Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
    Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
    Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
    Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.
    Steensma DP; List AF
    Mayo Clin Proc; 2005 May; 80(5):681-98. PubMed ID: 15887439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
    Panani AD; Roussos C
    Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies.
    Okada M; Suto Y; Hirai M; Shiseki M; Usami A; Okajima K; Teramura M; Mori N; Motoji T
    Cancer Genet; 2012; 205(1-2):18-24. PubMed ID: 22429594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.